ArticleFrontiers in oncology2025

Durable response to venetoclax, azacytidine, and ruxolitinib in chronic-phase myelofibrosis resistant to ruxolitinib: a case report and literature review.

Xiaohong Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.